美国临床化学分析仪市场 – 行业趋势和 2031 年预测

美国临床化学分析仪市场分析与见解

美国临床化学分析仪市场涉及美国各种型号的临床化学分析仪，例如 cobas、cobas integra 等。临床化学分析仪主要用于进行测试，可以指示各种健康状况，例如糖尿病和心脏病等。这些分析仪可以在独立实验室或医院中找到。临床化学分析仪以最短的周转时间提供准确的结果，通常是半自动化或全自动的。

分析仪能够更快地提供结果，有助于及早治疗相关疾病。推动临床化学分析仪市场增长的主要因素包括技术进步、慢性病患病率上升以及预防性医疗检测意识的提高。然而，化学分析仪的高成本和缺乏熟练的人员是美国临床化学分析仪市场增长的制约因素。

Data Bridge Market Research分析，美国临床化学分析仪市场规模预计将从2023年的54亿美元增至2031年的72亿美元，在2024年至2031年的预测期内，复合年增长率为3.9%。

市场定义

临床化学分析仪是一种自动化仪器，用于对各种类型的样本（包括血液、尿液、血清、血浆和脑脊液）进行各种生化测试。这些分析仪使医疗保健专业人员能够测量电解质、酶、激素、蛋白质、脂质和代谢物等物质的浓度，为诊断和监测疾病、评估器官功能和评估整体健康状况提供有价值的信息。

这些分析仪可用于各种实验室和其他临床环境，例如医院。临床化学分析仪的应用包括药物滥用检测、心脏标志物、代谢功能检测、糖尿病等医疗状况监测等。随着全球医疗保健系统优先考虑预防保健、早期疾病检测和个性化医疗，推动对先进诊断技术和解决方案的需求，临床化学分析仪市场预计将继续增长。

美国临床化学分析仪市场动态

本节旨在了解市场驱动因素、机遇、限制因素和挑战。下文将详细讨论所有这些内容：      

司机

• 慢性病患病率不断上升

慢性病患病率的上升可归因于不健康的生活方式，包括酗酒和吸烟。上述因素还会增加肥胖、高血压和胆固醇等健康风险，进而导致慢性病病例空前增加。随着疾病患病率的上升，早期诊断的需求也随之增加。

The chronic diseases such as diabetes, cardiovascular disorders, kidney diseases, and liver diseases often require regular monitoring and management. Clinical chemistry analyzers play a critical role in diagnosing these conditions, monitoring disease progression, and evaluating treatment effectiveness by measuring various biochemical parameters in bodily fluids such as blood and urine. These analyzers enable healthcare providers to perform comprehensive biochemical profiling, allowing for early detection of chronic diseases, assessment of organ function, and identification of risk factors. Early detection and proactive management of chronic diseases can help prevent complications, improve patient outcomes, and reduce healthcare costs.

Hence, the increasing prevalence of chronic diseases drives the demand for diagnostic testing, leading to the growth of the clinical chemistry analyzers market and therefore is acting as a driver for market growth.

Restraint

• High Cost Of Analyzer

The high cost of clinical chemistry analyzers can indeed be a significant barrier to their adoption and can restrain the growth of the market in several ways.

Limited Affordability: The healthcare facilities may find it challenging to afford the upfront capital investment required to purchase clinical chemistry analyzers. The high cost of acquisition can deter smaller clinics, and healthcare facilities with limited budgets from investing in these analyzers, thereby restricting their access to advanced diagnostic capabilities

Operational Expenses: In addition to the initial purchase cost, clinical chemistry analyzers often require ongoing maintenance, calibration, and consumables such as reagents and quality control materials. These operational expenses can further strain the budgets of healthcare facilities, particularly if they are already facing financial constraints. High operational costs may lead to reluctance in adopting or expanding the use of clinical chemistry analyzers.

The high cost of clinical chemistry analyzers can create barriers to entry for smaller manufacturers and startups, limiting competition in the market. As a result, there may be fewer options available to healthcare facilities, leading to less competitive pricing and slower innovation in the industry. This lack of competition can further contribute to the perception of clinical chemistry analyzers as expensive investments. Hence, the high prices of analyzers is expected to act as a restraint for the market growth.

Opportunity

• Rise in Preference for Preventive Health Check Ups

Preventive health check-ups are preventive actions performed for the initial detection of disease and safeguard against likely exposure to any disease in the future. The check-up is comprised of identification of disease and examinations of risk factors to limit loss at an early stage. Preventive health check-ups are performed with the help of various lab tests, including blood chemistry, hemoglobin, urinalysis, screening for prostate cancer, screening for ovarian cancer, ECG, lipid panel, and others.

Overall, the rising preference for preventive care creates a favorable market environment for clinical chemistry analyzers and other diagnostic technologies. As healthcare systems and consumers increasingly prioritize prevention and wellness, the demand for advanced diagnostic tools to support preventive care initiatives is expected to continue growing, and hence acting as an opportunity for the market growth.

Challenge

• Inaccurate Results of Tests

Patient safety emphasizes analyzing, reporting, and preventing medical errors, which often lead to adverse events and inappropriate clinical laboratory tests. Inappropriate clinical laboratory tests result in a greater chance of false-positive irregular outcomes, leading to serious consciousness.

Inaccurate results of tests are harmful financially and psychologically to the patients and to healthcare facilities which are decreasing authenticity, reliability and decreasing usage of clinical laboratory services due to these reason inaccurate results of tests is working as a challenge for the market.

Recent Developments

• In July 2023, F. Hoffmann-La Roche Ltd announced that it will showcase its latest product in the conference (American Association of Clinical Chemistry (AACC) Scientific Meeting). It includes featuring the newest innovations - the cobas 5800, which is a comapct, fully-automated molecular PCR-testing solution with a wide menu of assays. The product combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs. This has helped the company to make its unique position in the market
• In February 2024, Beckman Coulter, Inc. announced that it will launch new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai. The analyser is designed to address the complete needs of healthcare systems and has helped the company to expand its portfolio
• In July 2022, Thermo Fisher Scientific Inc. showcased its innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics at 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022). This has helped the company to display its innovative products and new technologies in the market
• 2023 年 8 月，雅培宣布其先进的 Alinity h 系列血液学系统已获得 FDA 批准。作为雅培 Alinity 系列诊断产品的一部分，它将帮助实验室运行全血细胞计数 (CBC)。这有助于该公司增加其产品供应

美国临床化学分析仪市场范围

美国临床化学分析仪市场根据产品类型、测试类型、模式、应用、样本、最终用户和分销渠道分为七个显著的细分市场。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

产品类型

• 试剂
• 仪器

根据产品类型，市场分为试剂和仪器。

测试类型

• 代谢组 (MP) 
• 普通化学测试 
• 血脂状况 
• 肝脏检查 
• 电解质面板 
• 肾脏概况 
• 特殊化学品测试 
• 甲状腺功能检查 

根据测试类型，市场分为代谢组（MP）、一般化学测试、脂质谱、肝脏组、电解质组、肾脏组、特殊化学测试和甲状腺功能组。

情态

• 台式
• 便携的
• 独立
• 其他的

根据形式，市场分为台式、便携式、独立式和其他。

应用

• 炎症性疾病 
• 糖尿病 
• 心血管疾病 
• 癌症 
• 滥用药物 
• 肾衰竭 
• 营养缺乏 
• 其他的 

根据应用，市场分为炎症性疾病、糖尿病、心血管疾病、癌症、药物滥用、肾衰竭、营养缺乏等。

标本

• 血清 
• 等离子体 
• 尿 
• 脑脊液 (CSF) 
• 血
• 羊水 
• 唾液
• 其他的 

根据样本，市场分为血清、血浆、尿液、脑脊液 (CSF)、血液、羊水、唾液和其他。

最终用户

• 医院
• 独立诊断实验室（医院外的实验室） 

根据最终用户，市场分为医院和独立诊断实验室（医院外的实验室）。

分销渠道

• 直接招标
• 零售销售
• 其他的

根据分销渠道，市场分为直接招标、零售和其他。

美国临床化学分析仪市场区域分析/见解

美国临床化学分析仪市场根据产品类型、测试类型、模式、应用、样本、最终用户和分销渠道分为七个显著的部分。

美国临床化学分析仪市场预计将增长，因为市场上有大型主要参与者，医疗保健领域的开发和研究活动增加。该地区早期的技术采用和成熟的市场促进了对先进解决方案的强劲需求。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测各个国家市场情景的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战以及销售渠道的影响。

竞争格局和美国临床化学分析仪市场份额分析

美国临床化学分析仪市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品批准、产品宽度和广度、应用主导地位以及产品类型生命线曲线。以上提供的数据点仅与公司对市场的关注有关。

该市场的一些主要市场参与者包括 F. Hoffmann-La Roche Ltd、Beckman Coulter, Inc.（丹纳赫的子公司）、赛默飞世尔科技公司、雅培、深圳迈瑞生物医疗电子股份有限公司、HORIBA、ELITech Group、Randox Laboratories Ltd.、Medica Corporation、JEOL Ltd.、TECO DIAGNOSTICS、FURUNO ELECTRIC CO.,LTD. 和日立高科技公司等。

SKU-59303